Successful treatment of CD7‐positive, undifferentiated acute leukemia with recombinant interferon alpha

Abstract

REFERENCESKurtzberg J, Waldmann TA, Davey MP, Binger SH, Moore JO, Hershfield MS, Haynes BF: CD7+, CD4-, CD8-acute leukemia: a syndrome of malignant pluripotent lymphohematopoietic cells. Blood 73:381, 1989. Matutes E, Pombo de Oliveira M, Foroni L, Morilla R, Catovsky D: The role of ultrastructural cytochemistry and monoclonal antibodies in clarifying the nature of undifferentiated cells in acute leukemia. Br J Haematol69:205, 1988. Van't Veer MB: The diagnosis of acute leukemia with undifferentiated or minimally differentiated blasts. Ann Hematol64:161, 1992. Bassan R, Biondi A, Benvestito S, Tini ML, Abbate M, Viero P, Barbui T, Rambaldi A: Acute undifferentiated leukemia with CD7+ and CD13+ immunophenotype. Lack of molecular lineage commitment and association with poor prognostic features. Cancer 69:396, 1992. De Me1 WCP, Hoftbrand AV, Giles FJ, Goldstone AH, Mehta AB, Ganeshagurt K: Alpha interferon therapy for haematological malignancies: correlation between in vivo induction of the 2',5' oligoadenylate system and clinical response. Br J Haematol 74:452, 1990.

Interferon‐alpha therapy in children with malignant diseases: Clinical experience in twenty‐four patients treated in a single pediatric oncology unit

“…The response of CD7-positive leukemic patients is of particular interest, since the CD7 antigen is expressed on immature hematopoietic stem cells that are not irreversibly committed to T-cell lineage. The leukemic transformation of this cell may cause a previously unrecognized leukemic syndrome that seems to be responsive to IFNa therapy [14]. Complete and partial responses were also seen in children with JMML, ET, disseminated LCH, astrocytoma, and neuroblasoma/ ganglioneuroblastoma.…”

Recombinant alpha-2a interferon treatment in a child with T-cell leukemia and chronic hepatitis B

“…During the past decade, several randomized controlled trials have demonstrated favorable results with alpha-interferon (a-IFN) therapy in patients with chronic hepatitis B [16,23,28,32]. Also some clinical trials with a-IFN produced hemotologic and cytogenetic remissions in lymphoproliferative and myeloproliferative disorders [5,9,10,15,26,29]. There are only a few reports concerning a-IFN treatment of children with refractory acute Iymphoblastic leukemia (ALL) [18,21,24,25].…”